

# **Meaningful Use of Electronic Health Record and Patient Utilization Outcomes within 30 Days of Hospital Discharge**

**Yanick N. Brice, PhD, MPA<sup>1</sup>; Karen E. Joynt Maddox, MD, MPH<sup>2</sup>;  
Grant A. Ritter, PhD<sup>3</sup>; Christopher P. Tompkins, PhD<sup>3</sup>**

**<sup>1</sup>Brown University School of Public Health, Providence, RI;**

**<sup>2</sup>Washington University School of Medicine, St Louis, MO;**

**<sup>3</sup>Brandeis University, Waltham, MA**

# Outline

- Causal Inference and Observational Data
- Background
- Study Goals & Design
- Data, Measures & Analytic Approach
- Principal Findings
- Limitations
- Policy Implications
- Conclusions
- Q & A

# Causal Inference and Observational Data

- Randomized Controlled Trial (RCT) is the **gold standard** for causal inference
- However, RCT data may be unavailable for several reasons, e.g., ethics, feasibility with respect to cost and timing, and other considerations
- Observational data, despite their major limitations—e.g., confounding, selection—may be the only source of information available
- When rigorously and carefully analyzed, they may provide invaluable insights into the worth of programs and interventions implemented (*Rubin 2008*)

## Background

- The HITECH Act authorized financial incentives to physicians and hospitals for adopting and using EHR to improve patient care
- Through the Meaningful Use (MU) Programs, launched in 2011 and to be implemented through 2021, hundreds of thousands of providers received incentives for complying with requirements that aim to stimulate the integration of EHR into daily practice
- MU policy priorities target, for instance, improvements in quality, safety, efficiency, and patient/caregiver education—while focusing on clinical information exchange and care coordination
- However, there is limited evidence supporting that compliance with MU requirements translates into better patient outcomes

## Study Goals & Design

To investigate the pattern of patient utilization outcomes to evaluate whether being admitted to MU vs. non-MU hospitals could:

- 1) Raise patient odds of timely ambulatory follow-up
- 2) Reduce patient odds of 30-day emergency department (ED) utilization
- 3) Further reduce patient odds of 30-day readmission—beyond a direct effect on readmission—via a timely ambulatory follow-up

**Posttest Only Quasi-Experimental Design**      NR      X      O<sub>MU</sub>

*(Shadish et al. 2002)*

NR indicates Nonrandom assignment. X: Treatment; O: outcomes

-----  
NR      O<sub>Non-MU</sub>

# Data, Measures & Analytic Approach

## Data Sources

- Medicare enrollment and claims files (2012), for roughly 180,000 patients
- Publicly available MU records for 160 hospitals (2011-2012), corresponding to MU Stage-1
- Hospital data (e.g., Provider of Services file, Healthcare Cost Report Information System)
- Market data (e.g., American Community Survey, Dartmouth Atlas of Health Care)

# Data, Measures & Analytic Approach

## Outcomes

*Patient utilization outcomes, including*

- 1) Timely ambulatory follow-up, defined as an evaluation and management service in ambulatory setting occurring within 14 days of discharge—*before* readmission *or* ED visit occurs
- 2) 30-day ED utilization
- 3) 30-day Readmission

All outcomes are binary and coded '1' for event occurrence, and '0' otherwise

# Data, Measures & Analytic Approach

## Exposure

*Being admitted to MU hospital*

- **Challenge:** Non-randomization of patients into MU vs. non-MU hospitals (or to receive or not a timely follow-up) suggests potential confounding at patient, market, and hospital level that could obscure relationship between exposure and outcome

## Analytic approach

To address these threats to internal validity, we use a propensity score-based analysis for bias reduction, that could mitigate potential imbalance at baseline and improve comparability between the two groups of patients

# Data, Measures & Analytic Approach

## **Inverse Probability Weighting** (*with stabilized weights*)

- *Inverse probability of treatment weighing* (IPTW) using the inverse of estimated propensity scores (PS)

Single-level logistic regression controlling for patient, market, and hospital covariates to obtain estimated PS

(*Guo & Fraser 2015; Thoemmes & West 2011*)

- *Variable selection approach*



Variables selected are of known theoretical or empirical or policy relevance—measured at baseline—that could potentially influence exposure and utilization outcomes

# Data, Measures & Analytic Approach

## Outcomes analysis

- Two-level weighted logistic regressions with patient, market and hospital controls to evaluate the associations of exposure with utilization outcomes
- Two-level weighted structural equation modeling (SEM) with regression adjustment—using the propensity scores of timely follow-up—to test mediation hypothesis of an indirect effect of being admitted to MU hospitals on 30-day readmission—via a timely ambulatory follow-up
- SAS 9.4 version 14.1 and MPlus 7.4 to estimate intervention effects using generalized linear mixed models (GLMM)

**Figure 1.** Distribution of Propensity Scores Among Hospitalized Patients



PS: propensity score. 0 = admitted to non-MU hospital vs. 1 = admitted to MU hospital.

0 = without timely follow-up vs. 1 = with timely follow-up.

## Principal Findings

- No evidence that patients admitted to MU hospitals had better utilization outcomes, including 1) higher odds of timely ambulatory follow-up; 2) lower odds of 30-day ED utilization; or 3) lower odds of 30-day readmission
- No evidence of a protective effect of a timely ambulatory follow-up against 30-day readmission
- However, strong associations of patient characteristics—e.g., prior utilization, illness severity—with utilization outcomes
- Strong associations of physicians' adoption of EHR with 30-day ED utilization and 30-day readmission

**Table 1. Predictors of Patient Utilization Outcomes within 30 Days of Hospital Discharge to Home**

| <i>Variable</i>                          | <i>Timely Ambulatory<br/>Follow-up*</i> | <i>p-value</i> | <i>30-Day ED<br/>Utilization</i> | <i>p-value</i> | <i>30-Day<br/>Readmission</i> | <i>p-value</i> |
|--|---|----------------|----------------------------------|----------------|-------------------------------|----------------|
| Admitted to MU hospital                  | <b>1.00 (0.95-1.07)</b>                 | <b>.873</b>    | <b>1.07(0.94-1.21)</b>           | <b>.294</b>    | <b>1.00 (0.93-1.06)</b>       | <b>.919</b>    |
| Prior Utilization                        | -                                       | -              | 1.11 (1.10-1.12)                 | <.0001         | 1.24 (1.21-1.27)              | <.0001         |
| Dually Eligible for<br>Medicare/Medicaid | 1.06 (1.01-1.12)                        | .020           | 0.93 (0.87-0.99)                 | .015           | 1.18 (1.12-1.24)              | <.0001         |
| Female Gender                            | 1.07 (1.04-1.11)                        | <.0001         | 0.99 (0.95-1.04)                 | .694           | 0.92 (0.88-0.96)              | <.0001         |
| Patient Cohort                           |   |                |                                  |                |                               |                |
| Medicine                                 | <i>Reference</i>                        |                | <i>Reference</i>                 |                | <i>Reference</i>              |                |
| Cardiovascular                           | 0.96 (0.89-1.04)                        | .317           | 1.37 (1.29-1.46)                 | <.0001         | 0.88 (0.80-0.96)              | .007           |
| Cardiorespiratory                        | 0.93 (0.88-0.98)                        | .010           | 1.14 (1.07-1.21)                 | <.0001         | 1.05 (0.99-1.11)              | .126           |
| Neurology                                | 1.07 (0.97-1.18)                        | .187           | 0.98 (0.91-1.06)                 | .684           | 0.82 (0.76-0.88)              | <.0001         |
| Surgery                                  | 0.86 (0.81-0.91)                        | <.0001         | 0.92 (0.86-0.98)                 | .007           | 0.63 (0.59-0.68)              | <.0001         |
| Patient MS-DRGs Weight                   |   |                |                                  |                |                               |                |
| Quartile 1 (lowest illness<br>severity)  | <i>Reference</i>                        |                | <i>Reference</i>                 |                | <i>Reference</i>              |                |
| Quartile 2                               | 0.92 (0.88-0.97)                        | .004           | 0.93 (0.88-0.98)                 | .008           | 1.29 (1.19-1.39)              | <.0001         |
| Quartile 3                               | 0.81 (0.77-0.86)                        | <.0001         | 0.82 (0.78-0.8)                  | <.0001         | 1.43 (1.28-1.59)              | <.0001         |
| Quartile 4                               | 0.92 (0.86-0.98)                        | .007           | 0.81 (0.74-0.88)                 | <.0001         | 1.55 (1.40-1.71)              | <.0001         |

# Limitations

## Data, population, and other interventions

- Evaluation focused on
  - 1) *Hospitals with Meaningful Use Stage-1*
    - Increased requirements, under future stages, may likely produce significant improvements in transitional care
  - 2) *Elderly patients in some specific markets*
    - Findings may not generalize to a younger, technologically savvier population, or to other areas
  - 3) *Patient follow-up using claims data*
    - Other methods of follow-up, e.g., phone calls & e-communications, not assessed
- Other interventions, such as the Hospital Readmissions Reduction Program (HRRP), may have biased results toward the null.

# Limitations

## Methods

- There are risks of model misspecifications, possibly associated with unmeasured confounders and/or omission of interactions or higher order terms, that can potentially bias the findings
- However, a comprehensive set of covariates was used and most plausible interactions tested
- Finally, the study is observational
- Cannot establish a definitive claim of causality

# Policy Implications

MU Program, in its early stages,

- Emphasizes data capture
- Does not address key patient-centered elements of care
- MU Program should focus on patient/caregiver health education and engagement

Improving care transitions will likely require additional interventions beyond timely clinical follow-up and hospitals using EHR systems

## Conclusions

- Observational data are invaluable sources of information for program evaluation
- RCT and observational data: Not a dichotomy; but differ in terms of strength of evidence: from well suited to poorly suited for drawing causal inferences (*Rubin 2008*)
- Critically important to separate design from analysis for objective causal inferences (*Rubin 2008*)
- PS methods aim to mimic RCTs. And like RCTs, they work best in large samples. How large?

# References

- Guo, S. and M. W. Fraser (2015). Propensity Score Analysis: Statistical Methods and Applications. Thousand Oaks, CA, Sage.
- Rubin, D. B. (2008). "For objective causal inference, design trumps analysis." Annals of Applied Statistics **2**(3): 808-840.
- Shadish, W. R., et al. (2002). Experimental and quasi-experimental designs for generalized causal inference. Boston, MA, Houghton Mifflin.
- Thoemmes, F. J. and S. G. West (2011). "The Use of Propensity Scores for Nonrandomized Designs with Clustered Data." Multivariate Behavioral Research **46**(3): 514-543.

**Thank You!**